Replies to post #13389 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The portion of the CC I’m referring to is the two minutes from 31:10 - 33:10 (in response to a question from Tom Shrader of Stifel).

It seems that MNTA has IP with respect to the reverse engineering of Copaxone that does not relate to ongoing submissions to the FDA by the sponsor of another generic product, thereby circumventing the Safe Harbor argument Amphastar used in the Lovenox patent case.